Active	Status	Sponsor type	Region	Phase	Filter
2 Active 0 Inactive 2 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Longo, Vito
CARRY-ON, NCT06663098: Atezolizumab and Rechallenge Chemotherapy in Relapsed Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC).	Not yet recruiting	2	142	Europe	Atezolizumab, humanized IgG1 monoclonal antibody against PD-L1, Carboplatin, re-challenge chemotherapy, Etoposide	Gruppo Oncologico Italiano di Ricerca Clinica, Roche Pharma AG	Extensive Stage Small Cell Lung Cancer (ES-SCLC)	08/28	06/29
THOR, NCT05623319 / 2020-004834-39: Pembrolizumab and Olaparib Treatment of Extensive Small Cell Lung Cancer (ES-SCLC)	Recruiting	2	60	Europe	Pembrolizumab/Olaparib	Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori, Merck Sharp & Dohme LLC	SCLC,Extensive Stage	10/26	10/26